A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine

Trial Profile

A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2016

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Trigemina
  • Most Recent Events

    • 11 May 2016 Status changed from active, no longer recruiting to completed.
    • 28 Oct 2015 Planned End Date changed from 1 Aug 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.
    • 28 Oct 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top